Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SciClone Pharmaceuticals (Holdings) Limited
  6. News
  7. Summary
    6600   KYG4271B1023

SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

(6600)
  Report
Delayed Hong Kong Stock Exchange  -  05/25 04:08:04 am EDT
8.500 HKD   -0.82%
05/20SciClone Pharma Updates Share Buyback Plan
MT
05/19Sciclone Pharmaceuticals Limited Approves Final Dividend for the Year Ended December 31, 2021
CI
04/19China Accepts SciClone Pharma's Clinical Trial Application for Neuroblastoma Immunotherapy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SciClone Pharmaceuticals Limited(SEHK:6600) added to S&P Global BMI Index

09/20/2021 | 12:00am EDT
share with twitter
share with LinkedIn
share with facebook

SciClone Pharmaceuticals (Holdings) Limited(SEHK:6600) added to S&P Global BMI Index


© S&P Capital IQ 2021
All news about SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
05/20SciClone Pharma Updates Share Buyback Plan
MT
05/19Sciclone Pharmaceuticals Limited Approves Final Dividend for the Year Ended December 31..
CI
04/19China Accepts SciClone Pharma's Clinical Trial Application for Neuroblastoma Immunother..
MT
03/29SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 67,787,426 shares..
CI
03/25SciClone Pharma's Per-Share Earnings Slip in 2021
MT
03/24SciClone Pharma Launches Buyback Program; Shares Rally 14%
MT
03/24SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended Decem..
CI
03/24Sciclone Pharmaceuticals Limited Recommends Final Dividend for the Year Ended December ..
CI
02/24SciClone Pharma Sees Higher Profit in 2021
MT
2021SciClone Pharmaceuticals Grants Nearly 4 Million Share Options
MT
More news
Financials
Sales 2022 2 791 M 419 M 419 M
Net income 2022 895 M 134 M 134 M
Net cash 2022 1 318 M 198 M 198 M
P/E ratio 2022 5,50x
Yield 2022 1,42%
Capitalization 4 921 M 740 M 740 M
EV / Sales 2022 1,29x
EV / Sales 2023 1,02x
Nbr of Employees 890
Free-Float 55,7%
Chart SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Duration : Period :
SciClone Pharmaceuticals (Holdings) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 7,26 CNY
Average target price 9,60 CNY
Spread / Average Target 32,2%
EPS Revisions
Managers and Directors
Hong Zhao President, CEO & Executive Director
Zhen Fu Li Chairman
Ping Chen Independent Non-Executive Director
Wendy Hayes Independent Non-Executive Director
Guo En Liu Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED-0.92%740
CSL LIMITED-6.04%93 360
SAMSUNG BIOLOGICS CO.,LTD.-10.52%45 499
BIOGEN INC.-15.58%29 662
WUXI BIOLOGICS (CAYMAN) INC.-39.22%28 538
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.41%21 450